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To examine the potential roles of human papillomavirus (HPV) in oesophageal squamous cell carcinoma (ESCC) development, we
examined the presence of HPV DNA in paraffin-embedded ESCC tissues collected from two areas with different ESCC incidence
rates in China, that is, Gansu (n¼26) and Shandong (n¼33), using PCR with SPF10 primers, or PCR with GP5þ/GP6þ primers
combined with Southern blot hybridisation. HPV genotype was determined by the INNO-LiPA HPV genotyping kit. HPV DNA was
detected in 17 cases (65%) in Gansu, where ESCC incidence is much higher than in Shandong, where HPV was positive in two
samples (6%). HPV genotypes 16 and 18 were detected in 79 and 16% of HPV-positive samples, respectively. Real-time PCR analysis
suggested the presence of integrated form of HPV DNA in all the HPV-16-positive samples, but its viral load was estimated to be
only o1–2 copies cell
 1. We could not detect HPV 16/18 E6 protein expression by immunostaining in any of the HPV-16-positive
samples. Neither p16
INK4a nor p53 expression was related to HPV presence in ESCCs. Further studies seem warranted to examine
the possible aetiological roles of HPV in ESCC.
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Human papillomavirus (HPV) is a nonenveloped, double-stranded
DNA virus with more than 90 genotypes. To date, molecular and
epidemiological studies have convincingly demonstrated that HPV
infection with certain genotypes, that is high-risk HPV, plays an
essential role in the development of uterine cervical cancer (Munoz
et al, 1994; Walboomers et al, 1999; Richman et al, 2002). In
malignant transformation of uterine cervical epithelia, integration
of high-risk HPV DNA into the host genome is considered an
important step (zur Hausen, 1991). Viral DNA integration leads to
disruption of the HPV 16 E2 gene (Kalantari et al, 1998), which is a
negative regulator of the E6/E7 promoter. Consequently, the E2
disruption leads to an increased expression of E6 and E7 viral
oncoproteins that target the p53 and retinoblastoma (pRb) tumour
suppressor proteins, respectively, and downregulates their anti-
tumour functions (zur Hausen, 1991; Romanczuk and Howley,
1992).
A number of studies reported HPV DNA detection in
extragenital cancers as well, although the aetiological involvement
of HPV in those malignancies is still controversial (Snijders et al,
1997; Gillison and Shah, 2003; Castillo et al, 2006). The association
between HPV and oesophageal squamous cell carcinoma (ESCC)
was first reported by Syrjanen in 1982. Since then, HPV infection
has received attention as a possible risk factor for ESCC
development (Syrjanen, 1982). An extensive review by Syrjanen
published in 2002 showed that HPV was positive in 22.9% of 1485
ESCCs analysed by in situ hybridisation (ISH) and in 15.2% of
2020 ESCCs analysed by PCR (Syrjanen, 2002). Accumulating
evidence on the presence of HPV DNA in normal oesophageal
epithelium (Chang et al, 2000; Zhou et al, 2003) and in cancer
precursor lesions (Pillai and Nair, 2000; Astori et al, 2001) suggests
an involvement of HPV in very early stages of the classical
dysplasia–carcinoma sequence. The notion was also supported by
the demonstration of HPV infection using serologic assays with
enzyme-linked immunosorbent assays (ELISAs) (Han et al, 1996).
HPV DNA detection rates in ESCC samples appear to be
different from area to area. An explanation, offered by Syrjanen in
his review, is the hypothesis that the contribution of oncogenic
HPVs to ESCC risk is higher in the areas with high ESCC risks
(Syrjanen, 1982). Indeed, recent studies conducted in areas with a
high ESCC risk showed fairly high detection rates of high-risk HPV
DNA in cancer specimens (Chang et al, 2000; Shen et al, 2002;
Farhadi et al, 2005). His hypothesis was also supported by a recent
study conducted in Anyang area in China. The study showed that
the detection rate of HPV, particularly high-risk genotypes, in
specimens collected by balloon cytology examinations appeared to
be higher in a village with a relatively high ESCC incidence when
compared to a village with a low ESCC risk (Li et al, 2001).
However, the finding could not be confirmed by a study conducted
among high-ESCC risk population in Linxian, China. In this study,
the infection of oesophageal cells with high-risk HPV genotypes
occurs in 13% of asymptomatic adults with no evidence of
squamous dysplasia and a similar proportion of individuals with
mild, moderate or severe dysplasia, suggesting that HPV infection
is not a major risk factor for ESCC in this high-risk Chinese
population (Gao et al, 2006). On top of that, an ESCC case–control
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sstudy nested in a cohort in Linxian, China, could not find any
evident case–control differences in the levels of serum antibody
against HPV 16, 18 or 73 (Kamangar et al, 2006). Although the
studies in Linxian could not confirm the relationship between HPV
and ESCC, the fact does not necessarily deny the presence of such a
relationship in other areas as the risk factor of ESCC is known to
be heterogeneous. In fact, nutritional factors were the most
important aetiological component of ESCC in Linxian (Taylor et al,
2003).
In the present study, we compared HPV DNA detection rates in
Gansu and Shandong, China, where age-adjusted mortality rates of
oesophageal cancer were 29 out of 100000 in 1996–2000 (Luo et al,
2002), and four out of 100000 in 1973–1975 (Junshi et al, 1991),
respectively. In HPV DNA detection, we used various techniques
including PCR with the sensitive short PCR fragment (SPF10)
primers (Ketler et al, 1999) and Southern blot hybridisation.
In addition, we examined HPV integration into the cancer cell
genome using real-time PCR, and expression of p53 and p16
INK4a
in order to shed light on the aetiological roles of HPV in ESCC
development.
SUBJECTS AND METHODS
A total of 59 paraffin-embedded tissue samples of ESCC diagnosed
during the period between 1994 and 2005 were obtained; 26 cases
from Gansu, a province located in the northwestern part of China
with a high incidence of ESCC, and 33 cases from Shandong, a
province in the east coast of China with a low incidence of ESCC.
Institutional Review Board of Kagoshima University Graduate
School of Medical and Dental Sciences, Japan, approved the
present study.
DNA extraction
Formalin-fixed, paraffin-embedded samples were cut into 10mm
slices and prepared according to the method described before
(Greer et al, 1995), followed by digestion with proteinase K
(200mgml
 1)a t5 5 1C overnight. The presence of DNA was
confirmed by PCR with b-globin (110bp) using PCO3 primer 50-
ACACAACTGTGTTCACTAGC-30 and PCO4 primer 50-CAACTT
CATCCACGTTCACC-30.
PCR amplification
The presence of HPV DNA was evaluated by PCR using GP5þ/
GP6þ primers (150bp), consensus primers for the HPV L1 gene
(De Roda Husman et al, 1995). The PCR reaction was performed in
a total volume of 25ml containing 1U of HotStar Taq (QIAGEN,
Hilden, Germany), 50mM of each primer, 0.2mM of each dNTP and
10  HotStar Taq PCR buffer as supplied by the enzyme
manufacturer (QIAGEN) (contains 1.5mM MgCl2, Tris–Cl, KCl,
(NH4)2SO4 pH 8.7). Different amounts of template for each sample
were used (2.5ml, 5ml and 10ml). The amplification was carried out
with initial enzyme activation at 951C for 15min, followed by
45 cycles that included a 1min denaturation step at 941C, a 2min
annealing step at 401C and a 1.5min chain elongation step at 721C;
and a final elongation at 721C for 5min. As positive control for
amplification, full genomes of HPV 6 and 18 (kindly donated by
Professor Harald zur Hausen, German Cancer Research Centre,
Heidelberg, Germany) were used, and water as template was used
as negative control. PCR products were visualised on 2% agarose
gel with ethidium bromide staining by electrophoresis.
Southern blot hybridisation
DNA from agarose gel was transferred by upward capillary blotting
to a Hybond Nþ nylon membrane (Amersham, Little Chalfont,
UK) using 0.4 M NaOH buffer. Hybridisation and detection of HPV
DNA was carried out using the ECL Nucleic Acid labelling and
detection kit (Amersham, UK). The probe used to detect HPV
DNA was obtained by purifying from agarose gel the GP5þ/
GP6þ PCR products from cloned HPV 6 and 18 using QIAEX II
Extraction kit (QIAGEN, Germany).
The INNO-LiPA genotyping system
A 65bp region of L1 gene of the HPV genome was amplified by
PCR using SPF10 biotinylated primers 50-GCiCAGGGiCACAAT
AATGG-30 and 50-GTiGTATCiACAACAGTAACAAA-30, where ‘i’
indicates inosine (Ketler et al, 1999). The PCR products were
visualised on 4% agarose gel with ethidium bromide staining by
electrophoresis, and 10ml of this PCR product was denaturated
and hybridised with specific oligonucleotide probes (25 HPV type-
specific probes) immobilised as parallel lines on a nitrocellulose
membrane strips, following the manufacturer’s instructions
(INNO-LiPA HPV genotyping kit, Innogenetics, Ghent, Belgium).
The 28 probes for 25 different HPV genotypes in each INNO-LiPA
strip are described elsewhere (Ketler et al, 1999). The strips were
interpreted with a labelled acetate overlay with lines indicating the
position of each probe relative to the reference mark.
Real-time PCR
Real-time PCR was performed with the ABI Prism 7000 Sequence
Detection System and SYBR-Green PCR master mix (PE, Applied
Biosystems, Foster, CA, USA). The amplification conditions were
10min at 951C and a two-step cycle of 951C for 15s and 601C for
60s for a total of 45 cycles. The used primer sets were as follows:
E6F: GAGAAACTGCAATGTTTCAGGACC; E6R: TGTATAGTT
GTTTGCAGCTCTGTGC; E2F: AACGAAGTATCCTCTCCTGAAA
TTATTAG and E2R: CCAAGGCGACGGCTTTG.
Those primers amplify a fragment of E6 (81bp) and E2 (76bp)
ORFs, respectively (Peitsaro et al, 2002). The final concentration of
primers was 0.5mM. Two standard curves for E2 and E6 fragments
were made by amplification of dilutions between 1 10
7 and
1 10
1 copies of HPV 16 cloned in pUC plasmid (kindly given by
Dr Massimo Tommasino, IARC, Lyon, France). There was a linear
relationship between the threshold cycle values plotted against the
log of the copy number over the entire range of dilutions. All the
experiments were made in duplicate. The specificity of amplifica-
tion was confirmed using dissociation analysis starting at 601C and
agarose gel electrophoresis of amplified products.
p16
INK4a, p53 and E6 HPV 16 and 18 protein
immunohistochemical staining (IHC)
Sections of a paraffin-embedded block with the thickness of 2–
3mm were placed on silane-coated glass slides, and deparaffinised
by passage through xylene. After the endogenous peroxidase
activity was blocked with 0.3% H2O2/methanol, the slides were
rehydrated with distilled water. For antigen retrieval, the slides
were heated in 0.01moll
 1 citrate buffer, pH 6.0, at 951C for 5min
(at 1211C for p53 and E6) and then left to cool at room temperature
(RT). After rinsing in 0.01moll
 1 phosphate-buffered saline (PBS),
pH 7.4, nonspecific antibody binding was reduced by incubating
the sections with 1% foetal bovine serum in PBS at RT for 30min.
Then, the sections were incubated overnight at RT with a mouse
monoclonal antibody against p16
INK4a protein (1:200 dilution,
GST-p16
INK4, PharMingen International, San Diego, CA, USA), p53
protein (1:50 dilution, DO-7, Dako Japan Co., Ltd, Kyoto, Japan)
or HPV 16 E6/18 E6 (1:50 dilution, SC-460, Santa Cruz
Biotechnology, Santa Cruz, CA, USA). After washing thoroughly
with PBS, the slides were incubated with biotinylated horse
anti-mouse IgG (1:200 dilution) for 30min, washed with PBS
followed by a 1:50 dilution (1:100 dilution for p53 and E6) of the
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savidin–biotin–peroxidase complex (Vectastain elite ABC kit,
Vector Laboratories, Burlingame, CA, USA) for an additional
30min and washed with PBS. The peroxidase signal was visualised
by treatment with DAB substrate-chromogen system (DAKO,
Japan) for 10min. Finally, the sections were stained lightly with
haematoxylin. In statistical analysis, the cases with less than 10%
cells stained positive were classified as negative cases, and the
other cases were regarded as positive cases (Xu et al, 2004).
Statistical analysis
Fisher’s exact test was conducted using STATA version 8. The
association between the presence of HPV 16 genome and tumour
differentiation was also examined using area as a covariate in a
multivariate logistic model by LogXact version 2.1. Tumour
differentiation was used as a binomial variable: 0¼poorly or
moderately differentiated and 1¼well differentiated. All the
P-values presented are two sided.
RESULTS
Table 1 summarises the clinicopathlogical features of ESCC cases
examined in the present study. The age of the patients ranged from
27 to 83 years with a mean of 61710 years. Male and female cases
numbered 48 (81%) and 11 (19%), respectively.
First, we examined all the 59 samples using GP5þ/GP6þ
primers for PCR and visualised only five HPV-positive cases in
agarose gel. When agarose-gel electrophoresis was replaced with
Southern blot hybridisation, HPV DNA was detected in an
additional 11 cases (in total 16 cases). As an alternative approach,
we examined cancer specimens using SPF10 primers, and
amplicons were visualised on 4% agarose gel. In this method,
HPV genome was confirmed to be present in all the 16 HPV-
positive samples identified by Southern blot hybridisation. In
addition, three cases became HPV positive in this new approach,
and, in total, we detected HPV DNA in 19 specimens, 17 samples
from Gansu (65%) and only two samples from Shandong (6%).
The difference in detection rates between the two regions was
highly significant (Po0.001, Fisher’s exact test). In the following,
we present the results using SPF10 primers.
Table 2 shows the detection rate of HPV according to
clinicopathological characteristics. HPV detection rate did not
show any statistically significant association with sex or age.
ESCCs from Shandong tended to be well differentiated, and Gansu
cases were predominated by moderately differentiated tumours.
There was no evidence indicating the association of high-risk HPV
presence with the expressions of p53 or p16
INK4a.
We could not detect HPV 16/18 E6 protein expression by IHC in
any of the HPV-16-positive samples.
Table 3 presents the HPV genotype identified by INNO-LiPA
HPV genotyping assay, where a single-strip analysis can identify
as many as 25 different HPV genotypes (Figure 1). The most
prevalent genotype was HPV 16, detected in 15 samples (79%),
followed by HPV 18, found in three samples (16%). We found
more than one HPV genotypes in three (16%) of the genotyped
samples. The coinfection of two high-risk HPV types, HPV 16/18
and HPV 16/51, were found in poorly differentiated tumours, while
the coinfection of one low- and one high-risk HPV (HPV 6/16)
was shown in a well-differentiated tumour. All the cases with
coinfection were male. The other factors, including age and the
expression of p16
INK4a and p53, showed no significant associations
with multiple HPV genotype detection.
Since the majority of HPV genotype detected was HPV 16, we
compared HPV-16-positive and HPV-negative tumours with
respect to clinicopathological features (data not shown). The area
difference was statistically significant (Po0.001, Fisher’s exact
test). The presence of HPV 16 genome was more frequent in
Table 1 Clinicopathological features of ESCC cases in this study
Shandong Gansu
N (%) N (%) P-value*
Total 33 (100) 26 (100)
Gender 0.740
Male 26 (79) 22 (85)
Female 7 (21) 4 (15)
Age (years)
a 0.562
o55 10 (31) 5 (19)
55–64 10 (31) 8 (31)
X65 12 (38) 13 (50)
Differentiation grade o0.001
Well 20 (61) 2 (8)
Moderate 8 (24) 14 (54)
Poor 5 (15) 10 (38)
p16
INK4a protein expression (%) 0.303
o10 23 (70) 17 (65)
10–79 3 (9) 6 (23)
X80 7 (21) 3 (12)
p53 protein expression (%) 0.064
o10 19 (58) 9 (35)
10–79 7 (21) 4 (15)
X80 7 (21) 13 (50)
*P-values were obtained by Fisher’s exact test.
aInformation on age was missing in a
case.
Table 2 HPV DNA detection in ESCC by PCR using SPF10 primers
All cases HPV positive HPV negative
N (%) N (%) N (%) P-value*
All 59 (100%) 19 (32%) 40 (68%)
Region o0.001
Shandong 33 (100) 2 (6) 31 (94)
Gansu 26 (100) 17 (65) 9 (35)
Gender 1.000
Male 48 (100) 16 (33) 32 (67)
Female 11 (100) 3 (33) 8 (67)
Age (years)
a 0.881
o55 15 (100) 4 (27) 11 (73)
55–64 18 (100) 6 (33) 12 (67)
X65 25 (100) 9 (36) 16 (64)
Differentiation grade 0.008
Well 22 (100) 2 (9) 20 (91)
Moderate 22 (100) 9 (41) 13 (59)





o10 40 (100) 16 (40) 24 (60)
10–79 9 (100) 2 (22) 7 (78)




o10 28 (100) 8 (29) 20 (71)
10–79 11 (100) 4 (36) 7 (64)
X80 20 (100) 7 (35) 13 (65)
*P-values were obtained by Fisher’s exact test.
aInformation on age was missing in a
case.
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smoderately and poorly differentiated carcinomas. The observed
association was statistically significant (P¼0.011, Fisher’s exact
test), but was not significant in a multivariate analysis adjusting
for area (P¼0.813).
Table 3 also summarises the results of real-time PCR analysis.
The quantity of HPV 16 E6 DNA ranged from 0.001 to 283.29
copies ng
 1 of genomic DNA. The results from repeated analyses
showed a difference less than 5% in all the cases except one, which
showed difference as large as 18%. Viral load was not related to
any clinicopathological features listed in Table 1 (data not shown).
E2/E6 ratio was determined by real-time PCR. In nine (60%) cases,
E2 DNA was not detected. In the rest of the cases, E2 DNA was
detected, but the E2/E6 ratio was less than unity.
DISCUSSION
In the present study, using PCR with SPF10 primers or PCR with
GP5þ/GP6þ primers combined with Southern blot hybridisa-
tion, we detected HPV DNA in 6% of Shandong samples while
HPV DNA was positive in 65% of samples from Gansu, where
ESCC incidence is much higher than in Shandong. Our finding
suggests possibility of a strong geographical difference in the
proportion of HPV-associated ESCCs. Note, however, that our
ESCC cases were convenient samples and, therefore, may not
represent the ESCC cases in the study areas. All HPV strains that
could be genotyped were found to be high-risk types. Prevalent
HPV genotypes were HPV 16 and 18, which were found in 79 and
16% of ESCC samples, respectively.
Detection rate varied upon the method used, with a high
sensitivity when using Southern blot hybridisation, and it was even
higher when using SPF10 primers PCR. However, even if such a
sensitive detection method was used, HPV genome was detectable
only in a small portion of cancer specimens collected from
Shandong (6%).
Using real-time PCR, we confirmed the presence of HPV 16 in 15
ESCC samples. Since HPV integration is considered to result in
deletion of the E2 gene (Jeon and Lambert, 1995), we determined
the status of HPV in the host cells on the basis of the E2/E6 ratio
(Peitsaro et al, 2002). When the ratio was equal to or higher than
unity, all the HPV genome was considered to be in an episomal
form and not integrated. On the other hand, the lack of amplified
HPV E2 genome was considered to indicate the integration of
all HPV genome into the host genome. When the E2/E6 ratio
was larger than zero and smaller than unity, we considered the
condition as the mixture of episomal and integrated forms, where a
portion of HPV genome was integrated into the host genome. In
the present study, the integrated form of HPV was detected in all
the HPV-positive specimens, including 60% of the samples without
detectable E2 DNA. We compared those findings with those of
Table 3 HPV genotypes by INNO-LiPA and HPV 16 viral load and physical status by real-time PCR in ESCC
Sample Area Genotype E6 copies/ng E2 copies/ng E2/E6 Status
1 Gansu 16 40.648 6.516 0.160 Mix
2 Gansu 16 0.019 0.007 0.372 Mix
3 Gansu 16 6.537 0.001 0.000 Integrated
4 Gansu 16 0.366 0.000 0.000 Integrated
5 Gansu 16 7.200 0.000 0.000 Integrated
6 Gansu 16 49.516 2.603 0.053 Mix
7
a Gansu 16 11.242 0.074 0.007 Mix
8 Gansu 16 0.436 0.000 0.000 Integrated
9 Gansu 16 283.293 20.908 0.074 Mix
10 Gansu 16 0.374 0.000 0.000 Integrated
11
b Gansu 16 5.696 0.000 0.000 Integrated
12 Gansu 16 0.351 0.005 0.015 Mix
13 Gansu 16 1.272 0.000 0.000 Integrated
14 Gansu 16 0.656 0.000 0.000 Integrated
15 Gansu 18 ND
c ND ND ND
16 Gansu Undetermined ND ND ND ND
17 Gansu Undetermined ND ND ND ND
18
d Shandong 16 0.001 0.000 0.000 Integrated
19 Shandong 18 ND ND ND ND
aSample with HPV 16/18 coinfection.
bSample with HPV 16/51 coinfection.
cNot done.








































Figure 1 Representative examples of INNO-LiPA HPV genotyping
assay. Strip 1: positive control of HPV types 6 and 18; strip 2: negative
control; strips 3–9 are ESCC samples; strip 3: HPV 16; strip 4: HPV 18; strip
5: HPV 16; strip 6: HPV 6 and 16; strip 7: HPV 16 and 18; strip 8: HPV 16
and strip 9: HPV 16 and 51.
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scervical cancers. Using 12 cervical cancer samples positive for HPV
16 (unpublished data), we determined E2/E6 ratio and found that
92% of the samples had a mixture of episomal and integrated
forms of HPV genome, and 8% of the samples had HPV integrated
into the host genome. The method, similar to ours, showed that
65–97% of the cervical cancer cases had HPV 16 integration,
which was frequently accompanied by episomal-form HPV
(Peitsaro et al, 2002; Arias-Pulido et al, 2006).
In the present study, a viral load in each specimen was expressed
as the number of HPV copies/genome equivalent or cell, using a
conversion factor of 6.6pg of DNA cell
 1 in order to make
comparisons with the results of other studies (Si et al, 2003). Real-
time PCR analysis showed a very low viral load, ranging from
0.001 to 283.29 copies ng
 1 of genomic DNA, which corresponds to
o1–2 copies cell
 1. The copy numbers of HPV 16 as low as what
was observed in the present study were also reported by a Chinese
study on oesophageal cancer tissues (o1 to 157 copies cell
 1)
(Si et al, 2003), and by a Finnish study on head and neck SCCs (4.6
to 49 copies cell
 1) (Koskinen et al, 2003). Considering the
presence of relatively low viral loads of HPV DNA in some cervical
carcinoma cell lines, for example SiHa (1–2 copies of HPV 16
cell
 1) and HeLa (10–50 copies of HPV 18 cell
 1), the low viral
load in ESCC may be sufficient to promote carcinogenesis,
especially if viral DNA is integrated into the cell (Si et al, 2005).
The integration of HPV DNA into the host genome, rather than the
mere presence of the episomal HPV DNA, may contribute to
oesophageal carcinogenesis.
A serological study in Linxian, China, where the ESCC risk is
extremely high (Kamangar et al, 2006), found no significant
association between seropositivity of HPV 16 and ESCC risk,
although serum antibodies against HPV antigens are considered
good markers of exposure to HPV in the past. Their results can be
explained by the decrease or loss of antibodies against HPV capsid
antigens during several decades after HPV infection until study
subjects were examined and their blood samples were drawn
(Lagergren et al, 1999). The viral load of HPV may also decrease
over those years and the viral-load decrease may also take place
during the process of cancer development. Therefore, the low viral
load and no expression of HPV 16 E6 protein in the present study
may be explained by the decrease of HPV viral load after infection
and/or a ‘hit and run’ mechanism, which has been proposed for the
association between bovine papillomavirus type 4 and oesophageal
cancer in cattle (Campo, 1987).
HPV E6 and E7 are considered to be the major oncoprotein
interfering with cell cycle regulation. The E6 protein of high-risk
HPV binds to p53, leading to rapid degradation of p53 through the
ubiquitin pathway (Scheffner et al, 1990). On the other hand, the
E7 protein binds and phosphorylates the tumour suppressor pRb
and inhibits its binding to E2F. Released E2F transcriptional factor
stimulates p16 transcription, leading to p16
INK4a overexpression,
which is also caused by the loss of the negative feedback from free
pRb, disrupted by HPV E7 (Scheffner et al, 1990; Lukas et al, 1995).
Indeed, overexpression of p16
INK4a is known to be observed in
cancers of the uterine cervix (Schorge et al, 2004), which is almost
always associated with HPV infection. In order to shed light on the
aetiological involvement of HPV, we conducted IHC of p53 and
p16
INK4a. However, we could not find any evidence indicating the
association of high-risk HPV presence with the expressions of p53
or p16
INK4a. Note, however, that p16
INK4a is frequently inactivated
through hypermethylation of p16
INK4a promoter and through
deletion at near-p16 loci (Serrano et al, 1993; Xing et al, 1999;
Tokunaga et al, 2002). In our study, we found a downregulation of
p16
INK4a expression in 68% of ESCC cases regardless of HPV
presence. The failure to detect p16
INK4a overexpression in HPV-
positive ESCC may therefore be explained by the fact that p16 is
downregulated through hypermethylation.
It should be noted that the cancer specimens used in the present
study contain noncancerous tissues, and that our findings do not
necessarily indicate the presence of HPV in carcinoma cells.
Studies showed the presence of HPV 16 E6 protein in the
cytoplasm and nucleus of ESCCs, which showed the presence of
HPV 16 in PCR analysis as well (Li et al, 2001; Yao et al, 2006). In
the present study, we could not detect viral E6 protein expression
by IHC in any of the HPV-16-positive samples.
Studies on the presence of HPV DNA in cervical samples showed
that 10% or more of clinical lesions contain at least two different
HPV genotypes (Rousseau et al, 2003; Schellekens et al, 2003). In
the present study, we observed multiple infection of HPV with
different genotypes in 16% of the genotyped samples, using INNO-
LiPA genotyping assay. Double infections in ESCC have also been
reported by a study in China (Lavergne and De Villiers, 1999).
Interestingly, in our study, the ESCC sample with double infection
of a high- and a low-risk HPV type (16/6) had the least number of
viral copies (0.001 copies ng
 1). It is of note that Silins et al. (1999)
suggested that infection with HPV 6 interfere with HPV 16 in
cervical carcinogenesis. Further studies on these interactions are
warranted as HPV coinfections in ESCC may affect the HPV life
cycle as well as disease progression as suggested by McLaughlin-
Drubin and Meyers (2004).
In conclusion, the present study showed that a large proportion
of ESCC specimens harbour HPV 16 genome in the integrated
form in a certain area with a high ESCC incidence. Detection rate
varied upon the method used, with a higher sensitivity when using
Southern blot hybridisation or SPF10 primers PCR. Real-time PCR
analysis suggested the presence of only a small number of HPV 16
copies in carcinoma cells. There was no HPV 16/18 E6 protein
expression, and on top of that, HPV 16 presence was not related to
the expression of p16
INK4a or p53 protein. Further studies seem
warranted to examine the possible aetiological roles of HPV in
ESCC.
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